Aller au contenu principal
Accès ouvert déclaré 2026 article

Molecular Markers of Antimalarial Drug Resistance in Plasmodium falciparum From Kumasi, Ghana, 2023

0Citations signalées, ce qui n’est pas une note de qualité
0Institutions déclarées
0Pays d’affiliation déclarés

Le résumé fourni par la source

Objectives: Artemisinin partial resistance has emerged in East Africa and is feared to spread across the continent, potentially compromising artemisinin‐based combination treatment. Molecular markers can serve as early warning signals for the development of specific drug resistance. We aimed at updating information on relevant resistance markers among Plasmodium falciparum from Kumasi, Ghana, collected in 2023. Methods: P. falciparum isolates were obtained from 200 patients with falciparum malaria. Mutations in pfk13 (propeller domain), pfcoronin (P76S), pfmdr1 (N86Y, Y184F, Y1246D) and pfaat1 (S258L) were genotyped. A subset of patients was microscopically examined for the presence of asexual malaria parasites on day‐3 of treatment with artemether‐lumefantrine. Results: 2.2% of isolates exhibited non‐synonymous pfk13 mutations including the candidate artemisinin partial resistance marker P527H in addition to S522C, C532S and I590V. Pfcoronin P76S, previously associated with artemether‐lumefantrine failure in malaria imported from Africa, was present in 29.7% and associated with a lower parasite density. The predominance of the pfmdr1 pattern N86‐184F‐D1246 (NFD) suggested impaired sensitivity to lumefantrine. Pfaat1 S258L was common at 64.7%. The resistance markers were not associated with each other, and they were not linked with day‐3 parasite positivity. Conclusions: While the efficacy of artemisinin‐based combination treatment in Ghana is still high, isolated critical pfk13 polymorphisms were identified as well as a considerable prevalence of a potentially relevant pfcoronin marker, against a background of pfmdr1 signals for impaired lumefantrine sensitivity. Continuous molecular monitoring is necessary to detect threats to artemisinin‐based combination treatment efficacy at an early stage.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.

Titre Crossref
Molecular Markers of Antimalarial Drug Resistance in <i>Plasmodium falciparum</i> From Kumasi, Ghana, 2023
Date Crossref
15/10/2025
Éditeur
Wiley
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les sujets associés

Malaria Research and ControlPharmaceutical Quality and CounterfeitingHistorical Medical Research and Treatments

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.